236 related articles for article (PubMed ID: 26447393)
1. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
[TBL] [Abstract][Full Text] [Related]
2. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
[TBL] [Abstract][Full Text] [Related]
3. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
4. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Doerr B; Mueller-Cohrs J; Pragst I; Morishima Y; Dickneite G
Anesthesiology; 2015 Feb; 122(2):387-98. PubMed ID: 25419685
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
6. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers.
Cheung YW; Barco S; Hutten BA; Meijers JC; Middeldorp S; Coppens M
J Thromb Haemost; 2015 Oct; 13(10):1799-805. PubMed ID: 26270625
[TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
8. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
Martin AC; Le Bonniec B; Fischer AM; Marchand-Leroux C; Gaussem P; Samama CM; Godier A
Int J Cardiol; 2013 Oct; 168(4):4228-33. PubMed ID: 23928345
[TBL] [Abstract][Full Text] [Related]
10. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.
Levy JH; Moore KT; Neal MD; Schneider D; Marcsisin VS; Ariyawansa J; Weitz JI
J Thromb Haemost; 2018 Jan; 16(1):54-64. PubMed ID: 29106076
[TBL] [Abstract][Full Text] [Related]
13. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
15. Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series.
Schultz NH; Lundblad R; Holme PA
J Med Case Rep; 2018 May; 12(1):138. PubMed ID: 29764497
[TBL] [Abstract][Full Text] [Related]
16. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate.
Zahir H; Brown KS; Vandell AG; Desai M; Maa JF; Dishy V; Lomeli B; Feussner A; Feng W; He L; Grosso MA; Lanz HJ; Antman EM
Circulation; 2015 Jan; 131(1):82-90. PubMed ID: 25403645
[TBL] [Abstract][Full Text] [Related]
18. Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate.
Sheikh-Taha M
Intern Emerg Med; 2019 Mar; 14(2):265-269. PubMed ID: 30414056
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
[TBL] [Abstract][Full Text] [Related]
20. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
Escolar G; Fernandez-Gallego V; Arellano-Rodrigo E; Roquer J; Reverter JC; Sanz VV; Molina P; Lopez-Vilchez I; Diaz-Ricart M; Galan AM
PLoS One; 2013; 8(11):e78696. PubMed ID: 24244342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
